Literature DB >> 28653665

Circulating Endocannabinoids: From Whence Do They Come and Where are They Going?

Cecilia J Hillard1.   

Abstract

The goal of this review is to summarize studies in which concentrations of circulating endocannabinoids in humans have been examined in relationship to physiological measurements and pathological status. The roles of endocannabinoids in the regulation of energy intake and storage have been well studied and the data obtained consistently support the hypothesis that endocannabinoid signaling is associated with increased consumption and storage of energy. Physical exercise mobilizes endocannabinoids, which could contribute to refilling of energy stores and also to the analgesic and mood-elevating effects of exercise. Circulating concentrations of 2-arachidonoylglycerol are very significantly circadian and dysregulated when sleep is disrupted. Other conditions under which circulating endocannabinoids are altered include inflammation and pain. A second important role for endocannabinoid signaling is to restore homeostasis following stress. Circulating endocannabinoids are stress-responsive and there is evidence that their concentrations are altered in disorders associated with excessive stress, including post-traumatic stress disorder. Although determination of circulating endocannabinoids can provide important information about the state of endocannabinoid signaling and thus allow for hypotheses to be defined and tested, the large number of physiological factors that contribute to their circulating concentrations makes it difficult to use them in isolation as a biomarker for a specific disorder.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28653665      PMCID: PMC5719092          DOI: 10.1038/npp.2017.130

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  204 in total

Review 1.  Endocannabinoid modulation in the olfactory epithelium.

Authors:  Esther Breunig; Dirk Czesnik; Fabiana Piscitelli; Vincenzo Di Marzo; Ivan Manzini; Detlev Schild
Journal:  Results Probl Cell Differ       Date:  2010

2.  Exercise deprivation increases negative mood in exercise-addicted subjects and modifies their biochemical markers.

Authors:  Hanna Karen Moreira Antunes; Geovana Silva Fogaça Leite; Kil Sun Lee; Amaury Tavares Barreto; Ronaldo Vagner Thomatieli Dos Santos; Helton de Sá Souza; Sergio Tufik; Marco Tulio de Mello
Journal:  Physiol Behav       Date:  2016-01-23

3.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Authors:  Luc F Van Gaal; Aila M Rissanen; André J Scheen; Olivier Ziegler; Stephan Rössner
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

4.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.

Authors:  Douglas Osei-Hyiaman; Michael DePetrillo; Pál Pacher; Jie Liu; Svetlana Radaeva; Sándor Bátkai; Judith Harvey-White; Ken Mackie; László Offertáler; Lei Wang; George Kunos
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

Review 5.  Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome.

Authors:  Neil B Ruderman; Charlotte Keller; Ann-Marie Richard; Asish K Saha; Zhijun Luo; Xiaoqin Xiang; Mercedes Giralt; Vladimir B Ritov; Elizabeth V Menshikova; David E Kelley; Juan Hidalgo; Bente K Pedersen; Meghan Kelly
Journal:  Diabetes       Date:  2006-12       Impact factor: 9.461

6.  Intense exercise increases circulating endocannabinoid and BDNF levels in humans--possible implications for reward and depression.

Authors:  E Heyman; F-X Gamelin; M Goekint; F Piscitelli; B Roelands; E Leclair; V Di Marzo; R Meeusen
Journal:  Psychoneuroendocrinology       Date:  2011-10-24       Impact factor: 4.905

7.  Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use.

Authors:  F Markus Leweke; Andrea Giuffrida; Dagmar Koethe; Daniela Schreiber; Brit M Nolden; Laura Kranaster; Miriam A Neatby; Miriam Schneider; Christoph W Gerth; Martin Hellmich; Joachim Klosterkötter; Daniele Piomelli
Journal:  Schizophr Res       Date:  2007-06-13       Impact factor: 4.939

8.  Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats.

Authors:  W-S Vanessa Ho; Sheila M Gardiner
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

9.  Diet-induced changes in n-3- and n-6-derived endocannabinoids and reductions in headache pain and psychological distress.

Authors:  Christopher E Ramsden; Daisy Zamora; Alexandros Makriyannis; JodiAnne T Wood; J Douglas Mann; Keturah R Faurot; Beth A MacIntosh; Sharon F Majchrzak-Hong; Jacklyn R Gross; Amber B Courville; John M Davis; Joseph R Hibbeln
Journal:  J Pain       Date:  2015-05-07       Impact factor: 5.820

10.  Endocannabinoids and related lipids in blood plasma following touch massage: a randomised, crossover study.

Authors:  Lenita Lindgren; Sandra Gouveia-Figueira; Malin L Nording; Christopher J Fowler
Journal:  BMC Res Notes       Date:  2015-09-29
View more
  108 in total

1.  Quantification of 24 circulating endocannabinoids, endocannabinoid-related compounds, and their phospholipid precursors in human plasma by UHPLC-MS/MS.

Authors:  Waldemar Röhrig; Susanne Achenbach; Birgit Deutsch; Monika Pischetsrieder
Journal:  J Lipid Res       Date:  2019-06-24       Impact factor: 5.922

2.  Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide).

Authors:  Erin C Hanlon
Journal:  Psychoneuroendocrinology       Date:  2019-10-04       Impact factor: 4.905

3.  In silico interaction analysis of cannabinoid receptor interacting protein 1b (CRIP1b) - CB1 cannabinoid receptor.

Authors:  Pratishtha Singh; Anjali Ganjiwale; Allyn C Howlett; Sudha M Cowsik
Journal:  J Mol Graph Model       Date:  2017-09-06       Impact factor: 2.518

Review 4.  Sleep deficiency and chronic pain: potential underlying mechanisms and clinical implications.

Authors:  Monika Haack; Norah Simpson; Navil Sethna; Satvinder Kaur; Janet Mullington
Journal:  Neuropsychopharmacology       Date:  2019-06-17       Impact factor: 7.853

5.  Increase in the circulating endocannabinoid 2-arachidonoylglycerol is associated with gabapentin use in septic ICU patients.

Authors:  Hershel Raff; David J Kramer; Cecilia J Hillard
Journal:  Endocrine       Date:  2017-09-05       Impact factor: 3.633

6.  Cannabis and Cannabinoids: From Synapse to Society.

Authors:  Margaret Haney; Matthew N Hill
Journal:  Neuropsychopharmacology       Date:  2018-01       Impact factor: 7.853

Review 7.  New aspects of hepatic endothelial cells in physiology and nonalcoholic fatty liver disease.

Authors:  Xinghui Sun; Edward N Harris
Journal:  Am J Physiol Cell Physiol       Date:  2020-05-06       Impact factor: 4.249

8.  Circulating Endocannabinoids and Mortality in Hemodialysis Patients.

Authors:  Hamid Moradi; Christina Park; Elani Streja; Donovan A Argueta; Nicholas V DiPatrizio; Amy S You; Connie M Rhee; Nosratola D Vaziri; Kamyar Kalantar-Zadeh; Daniele Piomelli
Journal:  Am J Nephrol       Date:  2020-01-14       Impact factor: 3.754

Review 9.  Meet Your Stress Management Professionals: The Endocannabinoids.

Authors:  Terri A deRoon-Cassini; Todd M Stollenwerk; Margaret Beatka; Cecilia J Hillard
Journal:  Trends Mol Med       Date:  2020-08-28       Impact factor: 11.951

10.  Circadian Misalignment of the 24-hour Profile of Endocannabinoid 2-Arachidonoylglycerol (2-AG) in Obese Adults.

Authors:  Erin C Hanlon; Rachel Leproult; Kara L Stuhr; Elizabeth M Doncheck; Cecilia J Hillard; Eve Van Cauter
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.